{
    "clinical_study": {
        "@rank": "57178", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B\u00ae) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim\u2122) at age 2, 4, and 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the immunogenicity and safety of a novel DTaP-IPV-Hep\n      B-PRP~T fully liquid combined hexavalent vaccine (study vaccine) administered at 2, 4, and 6\n      months of age compared to Sanofi Pasteur's DTaP-IPV//PRP~T combined vaccine (Pentaxim\u2122)\n      given at 2, 4, and 6 months of age and Hep B vaccine (Euvax B\u00ae) given at 1 and 6 months of\n      age in South Korean infants that received a birth dose of Hep B and born to mothers\n      documented to be serum anti-HBs Ag negative.\n\n      Primary Objective\n\n        -  To demonstrate the non-inferiority in terms of seroprotection (Diphtheria, Tetanus,\n           poliovirus types 1, 2, and 3, PRP-T, Hep B) and vaccine response for pertussis antigens\n           (pertussis toxoid [PT] and filamentous haemagglutinin [FHA]) of Group A versus Group B,\n           one month after the third dose of combined vaccines.\n\n      Secondary Objectives:\n\n        -  To further study the immunogenicity of the two vaccination schemes, before the first\n           dose and one month after the last dose of vaccines.\n\n        -  To study the safety after each and any dose of vaccines administered in the two\n           vaccination schemes"
        }, 
        "brief_title": "DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diphtheria", 
            "Tetanus", 
            "Pertussis", 
            "Haemophilus Influenzae Type b Infection", 
            "Poliomyelitis", 
            "Hepatitis B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Influenza, Human", 
                "Whooping Cough", 
                "Poliomyelitis", 
                "Tetanus", 
                "Tetany"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study participants who received a first dose of recombinant Hep B vaccine at birth will\n      receive either DTaP-IPV-Hep B-PRP~T combined vaccine at 2, 4, and 6 months of age + 3 doses\n      of Hep B vaccine or Hep B vaccine (Euvax B\u00ae) at 1 and 6 months of age and DTaP IPV//PRP~T\n      combined vaccine (Pentaxim\u2122) at 2, 4, and 6 months of age, according to the official\n      vaccination schedule for Hep B, DTaP, poliovirus, and Hib vaccinations in South Korea."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 30 to 40 days on the day of the first study visit\n\n          -  Born at full term of pregnancy (\u2265 37 weeks) and with a birth weight \u2265 2.5 kg\n\n          -  Informed consent form has been signed and dated by the parent(s) or other legally\n             acceptable representative\n\n          -  Participant and parent/legally acceptable representative are able to attend all\n             scheduled visits and to comply with all trial procedures\n\n          -  Born to known hepatitis B surface antigen (HBsAg) seronegative mother (documented\n             laboratory result of HBsAg assay from the maternal blood sample is available)\n\n          -  Have received one documented dose of Hep B vaccine at birth according to the national\n             recommendations.\n\n        Exclusion Criteria:\n\n          -  Participation in the 4 weeks preceding the trial inclusion or planned participation\n             during the present trial period in another clinical trial investigating a vaccine,\n             drug, medical device, or medical procedure\n\n          -  Receipt of any vaccine in the 4 weeks preceding any trial vaccination (except Bacille\n             Calmette Guerin (BCG) vaccine) or planned receipt of any vaccine in the 8 days\n             following any trial vaccination\n\n          -  Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis\n             B (except the dose of Hep B vaccine given at birth) diseases or Haemophilus\n             influenzae type b infection with either the trial vaccine or another vaccine\n\n          -  Past or current receipt of immune globulins, blood or blood-derived products or\n             planned administration during the trial\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,\n             since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent\n             for more than 2 consecutive weeks since birth)\n\n          -  Known personal or maternal history of Human Immunodeficiency Virus (HIV) or hepatitis\n             C seropositivity\n\n          -  History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Haemophilus\n             influenzae type b infection, confirmed either clinically, serologically, or\n             microbiologically\n\n          -  Known systemic hypersensitivity to any of the vaccine components, or history of a\n             life-threatening reaction to the vaccines used in the trial or to a vaccine\n             containing any of the same substances\n\n          -  Known thrombocytopenia, as reported by the parent/legally acceptable representative\n\n          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             contraindicating intramuscular vaccination\n\n          -  In an emergency setting, or hospitalized involuntarily\n\n          -  Chronic illness that, in the opinion of the investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  Moderate or severe acute illness/infection (according to investigator judgment) on\n             the day of vaccination or febrile illness (temperature \u2265 38.0\u00b0C). A prospective\n             participant should not be included in the study until the condition has resolved or\n             the febrile event has subsided\n\n          -  Identified as a natural or adopted child of the Investigator or employee with direct\n             involvement in the proposed study\n\n          -  History of seizures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Months", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "458", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094833", 
            "org_study_id": "A3L31", 
            "secondary_id": "U1111-1127-6896"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "DTaP-IPV-Hep B-PRP~T combined vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "DTaP-IPV//PRP~T and Hepatitis B vaccine", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Pentaxim\u2122", 
                    "Euvax B\u00ae"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Diphtheria", 
            "Tetanus", 
            "Pertussis", 
            "Haemophilus influenzae type b infection", 
            "Hepatitis B", 
            "DTaP-IPV-Hep - PRP-T vaccine"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301 724"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi do", 
                        "country": "Korea, Republic of", 
                        "zip": "425 707"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi Do", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeongsangnam do", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeongsangnam do", 
                        "country": "Korea, Republic of", 
                        "zip": "641 560"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeollabuk do", 
                        "country": "Korea, Republic of", 
                        "zip": "570 711"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonbuk", 
                        "country": "Korea, Republic of", 
                        "zip": "561 712"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kangwon do", 
                        "country": "Korea, Republic of", 
                        "zip": "220 701"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyunggi Do", 
                        "country": "Korea, Republic of", 
                        "zip": "420 717"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158 710"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137 701"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120 752"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "139 709"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "130 87"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon Gyeonggi do", 
                        "country": "Korea, Republic of", 
                        "zip": "442 723"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T Combined Vaccine at 2, 4, and 6 Months of Age Versus Sanofi Pasteur's DTaP IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Age + Hep B Vaccine at 1 and 6 Months of Age, in South Korean Infants Primed With Hep B at Birth", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Medical Director"
        }, 
        "overall_official": {
            "affiliation": "Sanofi Pasteur SA", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Anti-Diphtheria antibodies will be measured by a toxin neutralization test", 
                "measure": "Number of participants with anti-Diphtheria antibody concentrations \u2265 0.01 International Units (IU)/mL", 
                "safety_issue": "No", 
                "time_frame": "1 month post third vaccination"
            }, 
            {
                "description": "Anti-Tetanus antibodies will be measured by enzyme-linked immunosorbent assay (ELISA).", 
                "measure": "Number of participants with anti-Tetanus antibody concentrations \u2265 0.1 International unit (IU)/mL", 
                "safety_issue": "No", 
                "time_frame": "1 month post third vaccination"
            }, 
            {
                "description": "Anti-PT and anti-FHA antibodies will be measured by enzyme-linked immunosorbent assay (ELISA).", 
                "measure": "Number of participants with \u2265 4 fold increase in anti-PT and anti-FHA antibody concentrations (EU/mL) from 1 month pre-dose 1 to 1 month post-dose 3", 
                "safety_issue": "No", 
                "time_frame": "I month post dose 3"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094833"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Anti-Diphtheria antibodies will be measured by a toxin neutralization test", 
                "measure": "Number of participants with anti-Diphtheria antibody concentrations \u2265 0.01 IU/mL and \u2265 0.1 IU/mL International Units (IU)/mL", 
                "safety_issue": "No", 
                "time_frame": "Day 0 Pre-vaccination"
            }, 
            {
                "description": "Anti-Hepatitis B antibodies will be measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System using chemiluminescence detection technology", 
                "measure": "Number of participants with anti-Hepatitis B antibody concentrations \u2265 10 mIU/mL international unit (IU)/mL", 
                "safety_issue": "No", 
                "time_frame": "Day 0 Pre-vaccination"
            }, 
            {
                "description": "Anti-Diphtheria antibodies will be measured by a toxin neutralization test", 
                "measure": "Number of participants with anti Diphtheria antibody concentrations \u2265 0.1 IU/mL International Units (IU)/mL", 
                "safety_issue": "No", 
                "time_frame": "1 month post third vaccination"
            }, 
            {
                "description": "Solicited injection site reactions Tenderness, Erythema, and Swelling. Solicited systemic reactions Fever (temperature), Vomiting, Crying abnormal, Drowsiness, Appetite loss, and Irritability.", 
                "measure": "Number of participants reporting solicited injection site and solicited systemic reactions, unsolicited adverse events, and serious adverse events following vaccination with either DTaP-IPV-Hep B-PRP~T combined vaccine or Pentaxim\u2122 and Euvax B\u00ae vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and up to Day 180 post-vaccination"
            }, 
            {
                "description": "Vaccine response defined as: Post-dose 3 anti-PT and anti-FHA antibody concentrations in ELISA units (EU)/mL \u2265 4 x Lower Limit of Quantitation (LLOQ) if pre-vaccination concentration is < 4 x LLOQ or \u2265 pre-vaccination concentration if pre-vaccination concentrations \u2265 4 x LLOQ", 
                "measure": "Number of participants with response to vaccine Pertussis toxoid (PT) and Filamentous Haemagglutinin (FHA) antigens", 
                "safety_issue": "No", 
                "time_frame": "1 month post third vaccination"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}